Abstract
Members of the ErbB family of receptors have been implicated in regulation of androgen receptor (AR) activity. Ebp1, an ErbB-3 binding protein recently cloned in our laboratory, possesses an LXXLL motif important in mediating interactions with nuclear hormone receptors. Therefore, we sought to determine if Ebp1 could bind AR and influence AR transcriptional activation potential. We demonstrate in this study that Ebp1 bound to AR in vitro and in vivo, and that this binding was increased by androgen treatment. The C terminal 79 amino acids of Ebp1 were sufficient to bind AR. The N terminal domain of AR was responsible for binding Ebp1. Ligand-mediated transcriptional activation of both artificial and natural AR regulated promoters was inhibited by ectopic expression of ebp1 in transient transfection systems. Ebp1 deletion mutants that either lacked the C terminal AR binding region or had a mutated LXXLL motif failed to inhibit AR activated transcription. PSA expression from its endogenous promoter was also decreased in LNCaP prostate cancer cells overexpressing Ebp1. The growth of AR positive LNCaP cells was inhibited by ectopic expression of ebp1, but mutants that failed to repress transcription did not inhibit cell growth. These studies suggest that Ebp1 may play a role in the function of the AR and provide a link between ErbB receptors and the AR.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aarnisalo P, Palvimo JJ, Janne OA . 1998 Proc. Natl. Acad. Sci. USA 95: 2122–2127
Aarnisalo P, Santti H, Poukka H, Palvimo JJ, Janne OA . 1999 Endocrinology 140: 3097–3105
Alen P, Claessens F, Verhoeven G, Rombauts W, Peeters B . 1999 Mol. Cell. Biol. 19: 6085–6097
Bacus SS, Gudkov AV, Zelnick CR, Chin D, Stern R, Stancovski I, Peles E, Ben Baruch N, Farbstein H, Lupu R . 1993 Cancer Res. 53: 5251–5261
Bacus SS, Yarden Y, Oren M, Chin DM, Lyass L, Zelnick CR, Kazarov A, Toyofuku W, Gray-Bablin J, Beerli RR, Hynes NE, Nikiforov M, Haffner R, Gudkov A, Keyomarsi K . 1996 Oncogene 12: 2535–2547
Barton J, Blackledge G, Wakeling A . 2001 Urology 58: 114–122
Bevan CL, Hoare S, Claessens F, Heery DM, Parker MG . 1999 Mol. Cell. Biol. 19: 8383–8392
Craft N, Shostak Y, Carey M, Sawyers CL . 1999 Nat. Med. 5: 280–285
Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H . 1994 Cancer Res. 54: 5474–5478
Fondell JD, Ge H, Roeder RG . 1996 Proc. Natl. Acad. Sci. USA 93: 8329–8333
Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ . 1997 Oncogene 15: 2705–2716
Gross M, Liu B, Tan J, French FS, Carey M, Shuai K . 2001 Oncogene 20: 3880–3887
Hayes SA, Zannegar M, Sharma M, Yang F, Peehl DM, ten Dijke P, Sun Z . 2001 Cancer Res. 61: 2112–2118
He B, Kemppainen JA, Wilson EM . 2000 J. Biol. Chem 275: 22986–22994
Heery DM, Kalkhoven E, Hoare S, Parker MG . 1997 Nature 387: 733–736
Jenster G . 2000 J. Pathol 191: 227–228
Kallioniemi OP, Visakorpi T . 1996 Adv. Cancer Res. 68: 225–255
Kemppainen JA, Lane MV, Sar M, Wilson EM . 1992 J. Biol. Chem. 267: 968–974
Knudsen KE, Cavenee WK, Arden KC . 1999 Cancer Res. 59: 2297–2301
Lessor TJ, Hamburger AW . 2001 Mol. Cell Endocrinol. 175: 185–191
Lessor TJ, Yoo JY, Xia X, Woodford N, Hamburger AW . 2000 J. Cell Physiol. 183: 321–329
Lu ML, Schneider MC, Zheng Y, Zhang X, Richie JP . 2001 J. Biol. Chem. 276: 13442–13451
Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng D, Salup R . 1997 Cancer J. Sci. Am. 3: 21–30
Mellon K, Thompson S, Charlton RG, Marsh C, Robinson M, Lane DP, Harris AL, Horne CH, Neal DE . 1992 J. Urol. 147: 496–499
Morote J, de Torres I, Caceres C, Vallejo C, Schwartz S, Reventos J . 1999 Int. J. Cancer 84: 421–425
Myers RB, Srivastava S, Oelschlager DK, Grizzle WE . 1994 J. Natl. Cancer Inst. 86: 1140–1145
Nagy L, Kao HY, Love JD, Li C, Banayo E, Gooch JT, Krishna V, Chatterjee K, Evans RM, Schwabe JW . 1999 Genes Dev. 13: 3209–3216
Perissi V, Staszewski LM, McInerney EM, Kurokawa R, Krones A, Rose DW, Lambert MH, Milburn MV, Glass CK, Rosenfeld MG . 1999 Genes Dev. 13: 3198–3208
Petre CE, Wetherill YB, Danielsen M, Knudsen KE . 2002 J. Biol. Chem. 277: 2207–2215
Prigent SA, Lemoine NR, Hughes CM, Plowman GD, Selden C, Gullick WJ . 1992 Oncogene 7: 1273–1278
Radomski N, Jost E . 1995 Exp. Cell Res. 220: 434–445
Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z, Balk SP, Janne OA, Palvimo JJ, Pestell RG . 2001 Mol. Endocrinol. 15: 797–811
Sharma D, Fondell JD . 2000 Mol. Endocrinol. 14: 2001–2009
Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M . 2000 J. Natl. Cancer Inst. 92: 1918–1925
Slagsvold T, Kraus I, Fronsdal K, Saatcioglu F . 2001 J. Biol. Chem. 276: 31030–31036
Stocklin E, Wissler M, Gouilleux F, Groner B . 1996 Nature 383: 726–728
Ware JL, Maygarden SJ, Koontz Jr WW, Strom SC . 1991 Hum. Pathol. 22: 254–258
Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan D, Hung MC . 2000 Cancer Res. 60: 6841–6845
Whitfield GK, Jurutka PW, Haussler CA, Haussler MR . 1999 J. Cell Biochem. Suppl 32–33 110–122
Wilson EM, Simental JA, French FS, Sar M . 1991 Ann. NY Acad. Sci. 637: 56–63
Xia X, Lessor TJ, Zhang Y, Woodford N, Hamburger AW . 2001a Biochem. Biophys. Res. Commun. 289: 240–244
Xia X, Cheng A, Lessor T, Zhang Y, Hamburger AW . 2001b J. Cell Physiol. 187: 209–217
Xia X, Serrero G . 1999 Biochem. J. 341: 831–837
Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C . 1999 Nat. Med. 5: 280–285
Yoo JY, Wang XW, Rishi AK, Lessor T, Xia XM, Gustafson TA, Hamburger AW . 2000 Br. J. Cancer 82: 683–690
Zhou YC, Waxman D . 1999 J. Biol. Chem. 274: 29874–29882
Acknowledgements
This work was supported in part by the Susan Komen Foundation and NIH R01 CA76047 and R21 088882-01 (to AW Hamburger). We thank Dr Olli Janne for the androgen responsive reporter gene and AR expression plasmids, and Dr Martin Gleave for the PSA reporter construct.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, Y., Fondell, J., Wang, Q. et al. Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1. Oncogene 21, 5609–5618 (2002). https://doi.org/10.1038/sj.onc.1205638
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205638
Keywords
This article is cited by
-
The roles of multifunctional protein ErbB3 binding protein 1 (EBP1) isoforms from development to disease
Experimental & Molecular Medicine (2020)
-
The expression and prognostic role of EBP1 and relationship with AR in HER2+ breast cancer
Virchows Archiv (2020)
-
The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells
Molecular and Cellular Biochemistry (2015)
-
EBP1 suppresses growth, migration, and invasion of thyroid cancer cells through upregulating RASAL expression
Tumor Biology (2015)
-
The downregulation of ErbB3 binding protein 1 (EBP1) is associated with poor prognosis and enhanced cell proliferation in hepatocellular carcinoma
Molecular and Cellular Biochemistry (2014)